Psychedelics and Depression
Psilocybin shows promise in treating major depression, often providing relief through immersive experiences in controlled settings. While microdosing is discussed, it appears less impactful compared to higher doses administered during clinical sessions. The underlying mechanisms involve neuroplasticity and a complex interplay of neurotransmitters, suggesting that individual responses to psychedelics may vary significantly.In this clip
From this podcast
Huberman Lab
Understanding & Conquering Depression | Huberman Lab Podcast #34
Related Questions
What does the research say about psilocybin microdosing as discussed in the episode Dr. Matthew Johnson: Psychedelics for Treating Mental Disorders | Huberman Lab Podcast #38 and the clip Microdosing Insights?
What does Andrew Huberman say about microdosing psilocybin in the episode Dr. Robin Carhart-Harris: The Science of Psychedelics for Mental Health | Huberman Lab Podcast and the clip Psychedelics Research Insights?
What further research is being done on psilocybin for depression as discussed in the episode Understanding & Conquering Depression | Huberman Lab Podcast #34 and the clip Psychedelics and Depression?